Selecting and Dosing IL-17 Inhibitors in Psoriasis

Video content above is prompted by the following:

• How do you decide if an IL-17 inhibitor is an appropriate therapeutic option for a patient with plaque psoriasis? What patient factors do you take into consideration?
• What factors impact selection of an IL-17 inhibitor for a patient?
  • How does IL-17 clinical trial data affect your treatment decisions vs real-world factors (access, cost, etc)?
• Describe the differences in dosing for the IL-17 inhibitors in psoriasis. Do dosing considerations influence your clinical decision-making when prescribing these agents?
  • Secukinumab: 300 mg weekly for 5 weeks and then monthly thereafter; option for 150 mg dose in some patients and 2 different device types
  • Ixekizumab: 160 mg (2 80 mg injections) at week 0, 80 mg every 2 weeks for weeks 2 to 12 and then 80 mg monthly thereafter; 2 different device types
  • Brodalumab: 210 mg weekly for 3 weeks and then every 2 weeks thereafter
  • Bimekizumab: 320 mg every 4 weeks for 16 weeks and then every 8 weeks thereafter; consider continuing 320 mg every 4 weeks for patients weighing over 120 kg; 2 different device types in 160 mg or 320 mg doses